Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of tafasitamab + lenalidomide + rituximab in relapsed/refractory follicular and marginal zone lymphoma
2023-504684-16-00Phase 3Authorised
- Sponsor
- Incyte
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) comparing Tafasitamab + lenalidomide + rituximab with Lenalidomide + rituximab (plus placebo) (2 arms). Primary endpoint: Progression-free survival in follicular lymphoma population (primary). Planned start Jun 2021; status: authorised.
02
Drugs
tafasitamab
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2023-504684-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504684-16-00.